| Dr Nurelign G Abebe, MD | |
|
1050 West 10th Street, Rolla, MO 65401 | |
| (573) 364-9000 | |
| (573) 458-8489 |
| Full Name | Dr Nurelign G Abebe |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 30 Years |
| Location | 1050 West 10th Street, Rolla, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154587038 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2011018206 (Missouri) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 2011018206 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rolla Dialysis | Rolla, MO | Dialysis facility |
| Phelps County Regional Medical Center | Rolla, MO | Hospital |
| Ssm Health St Mary's Hospital Jefferson City | Jefferson city, MO | Hospital |
| Texas County Memorial Hospital | Houston, MO | Hospital |
| Salem Memorial District Hospital | Salem, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cole Physician Services Llc | 0648420810 | 28 |
| Pcrmc Medical Group, Inc | 1557454063 | 90 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
| Entity Name | Saint Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20031111000818 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
| Entity Name | Phelps County Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891766051 PECOS PAC ID: 2860391158 Enrollment ID: O20040106000405 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
| Entity Name | Ssm Audrain Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841334836 PECOS PAC ID: 3678481827 Enrollment ID: O20040129000368 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
| Entity Name | Pcrmc Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124237227 PECOS PAC ID: 1557454063 Enrollment ID: O20070829000437 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
| Entity Name | Cole Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144578659 PECOS PAC ID: 0648420810 Enrollment ID: O20121024000296 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nurelign G Abebe, MD 1050 W 10th St, Rolla, MO 65401-2905 Ph: (573) 364-9000 | Dr Nurelign G Abebe, MD 1050 West 10th Street, Rolla, MO 65401 Ph: (573) 364-9000 |
News Archive
It was supposed to be so easy this election year for Republican congressional candidates. All they would have to do was shout "repeal Obamacare!" and make a crack about government doctors and broken websites, and they could coast into office on a wave of public fury. ... But it has not quite worked out that way. ... That sentiment conflicts with the Republican playbook, which party leaders are suddenly trying to rewrite. The result has been an incoherent mishmash of positions, as candidates try to straddle a widening gap between blind hatred of health reform and the public's growing recognition that much of it is working (6/1).
Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche's anticancer biologic, Herceptin (trastuzumab).
Stand Up To Cancer, the charitable initiative aimed at bringing new treatments to cancer patients quickly, today announced Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.
Cancer, heart and circulatory system diseases cause two thirds of all deaths in Europe. Three research projects at this week's Enabling Grids for E-sciencE (EGEE) User Forum in Uppsala, Sweden, are demonstrating ways that modern computing techniques can investigate today's biggest killers.
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine and Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present preliminary TZP-102 Phase 2 data at this year's ACG annual meeting. The event is being held at the Henry B. Gonzalez Convention Center in San Antonio TX, October 15-20, 2010. Professor Wo is scheduled to speak on Wednesday, October 20th at 8:50am in Ballroom C1.
› Verified 9 days ago
Dr. Donald L James, DO Nephrology Medicare: Medicare Enrolled Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-364-7545 Fax: 573-368-3672 | |
Bohdan A Lebedowicz, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-364-9000 Fax: 573-202-2440 | |
Dr. James J Spadaro Jr., M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-308-1301 Fax: 573-202-2480 | |
Dr. Hadi Bhurgri, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-458-3580 Fax: 573-202-2408 | |
John Robertson Carr, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1000 W 10th St, Rolla, MO 65401 Phone: 573-458-8899 | |
Dr. Dmitry Familtsev, M.D., PH.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1050 W 10th St, Rolla, MO 65401 Phone: 573-308-1301 Fax: 573-202-2480 | |
Dr. Thomas F Martin, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1050 W 10th St, Ste 500, Rolla, MO 65401 Phone: 573-308-1301 Fax: 573-308-1305 |